|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Alaunos_Therapeutics
|
|
gptkbp:ceo
|
gptkb:Franz-Werner_Haas
|
|
gptkbp:clinical_trial
|
gptkb:Cure_Vac's_COVID-19_vaccine_trial
gptkb:Cure_Vac's_m_RNA_cancer_vaccine
gptkb:Cure_Vac's_m_RNA_vaccine_for_HIV
gptkb:Cure_Vac's_m_RNA_vaccine_for_Zika_virus
gptkb:Cure_Vac's_m_RNA_vaccine_for_bladder_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_breast_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_cervical_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_colorectal_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_esophageal_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_head_and_neck_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_hepatitis_B
gptkb:Cure_Vac's_m_RNA_vaccine_for_influenza
gptkb:Cure_Vac's_m_RNA_vaccine_for_kidney_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_liver_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_lung_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_melanoma
gptkb:Cure_Vac's_m_RNA_vaccine_for_ovarian_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_pancreatic_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_prostate_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_rabies
gptkb:Cure_Vac's_m_RNA_vaccine_for_thyroid_cancer
gptkb:Cure_Vac's_m_RNA_vaccine_for_tuberculosis
gptkb:drug
Phase 1
Phase 2
Phase 3
biopharmaceuticals
C Vn Co V Phase 1/2 trial
Cure Vac's m RNA vaccine for glioblastoma.
Cure Vac's m RNA vaccine for sarcoma
Cure Vac's m RNA vaccine for testicular cancer
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:University_of_Pennsylvania
gptkb:Coalition_for_Epidemic_Preparedness_Innovations_(CEPI)
Lilly
|
|
gptkbp:employees
|
over 200
~300 (2021)
|
|
gptkbp:focus
|
m RNA technology
|
|
gptkbp:focus_area
|
oncology
rare diseases
autoimmune diseases
cardiovascular diseases
infectious diseases
vaccine development
respiratory diseases
neurological diseases
metabolic diseases
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Ingmar_Hoerr
|
|
gptkbp:goal
|
develop m RNA-based medicines
|
|
gptkbp:headquarters
|
gptkb:Tübingen,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cure Vac AG
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
over 200 patents
|
|
gptkbp:investment
|
$100 million
$100 million (2020)
|
|
gptkbp:ipo
|
gptkb:2020
|
|
gptkbp:is_vulnerable_to
|
gptkb:drug
C Vn Co V
|
|
gptkbp:market
|
global biotechnology market
|
|
gptkbp:market_cap
|
$1 billion
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:temple
gptkb:Johnson_&_Johnson
gptkb:Zymeworks
gptkb:Takeda_Pharmaceutical_Company
gptkb:Sanofi
gptkb:Bayer_AG
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Moderna
gptkb:Sangamo_Therapeutics
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Eli_Lilly_and_Company
gptkb:Vertex_Pharmaceuticals
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Illumina
gptkb:Novartis
Merck K Ga A
|
|
gptkbp:platform
|
C Vn Co V
C V8102
Cure Vac m RNA technology
C V7202
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:European_Medicines_Agency
|
|
gptkbp:research_focus
|
infectious diseases
cancer vaccines
cancer immunotherapy
|
|
gptkbp:revenue
|
€ 20 million (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:subsidiary
|
gptkb:Cure_Vac_N._V.
gptkb:Cure_Vac_Biologics
gptkb:Cure_Vac_Inc.
|
|
gptkbp:symbol
|
CVAC
|
|
gptkbp:technology
|
RNA-based therapeutics
m RNA vaccines
m RNA therapeutics
|
|
gptkbp:type_of
|
gptkb:Company
|
|
gptkbp:bfsParent
|
gptkb:Cure_Vac
gptkb:Evotec
|
|
gptkbp:bfsLayer
|
3
|